- In early August 2026, BioCryst Pharmaceuticals, Inc. reported second quarter revenue of US$218.25 million and net income of US$78.4 million, alongside raising its full‑year 2026 revenue outlook to US$690 million–US$715 million and filing a US$63.14 million shelf registration for 7,000,000 ESOP‑related shares.
- While the quarter showed a sharp swing to profit, the six‑month period still reflected a US$643.42 million net loss, underscoring how one strong quarter sits against a much weaker year‑to‑date picture.
- We’ll now examine how this upgraded full‑year revenue guidance reshapes BioCryst’s existing investment narrative built around ORLADEYO and rare diseases.
Find 50 companies with promising cash flow potential yet trading below their fair value.
BioCryst Pharmaceuticals Investment Narrative Recap
To own BioCryst, you need to believe ORLADEYO can sustain and broaden its role in hereditary angioedema while the rare disease pipeline gradually adds new revenue streams. The upgraded 2026 revenue outlook reinforces ORLADEYO’s importance as the key near term catalyst, but the sharp year to date loss highlights how reliant the story still is on one drug and how vulnerable it remains to competitive and market pressures in HAE.
The most relevant update here is the higher full year 2026 revenue guidance to US$690 million to US$715 million, up from US$635 million to US$660 million. This tighter, higher range sets a new bar for ORLADEYO’s commercial performance and will likely shape how investors judge execution against the core catalyst of sustained HAE revenue, especially as BioCryst exits internal discovery and leans more heavily on external innovation.
Yet behind the stronger guidance, investors should also be aware of how concentrated BioCryst’s fortunes still are in ORLADEYO and what happens if...
Read the full narrative on BioCryst Pharmaceuticals (it's free!)
BioCryst Pharmaceuticals’ narrative projects $930.1 million in revenue and $131.3 million in earnings by 2029.
Uncover how BioCryst Pharmaceuticals' forecasts yield a $21.30 fair value, a 119% upside to its current price.
Exploring Other Perspectives
Before this quarter, the most optimistic analysts were already assuming BioCryst could reach about US$1.0 billion in revenue and roughly US$346 million in earnings by 2029, which is far more bullish than consensus. Today’s stronger guidance and profitable quarter could either support that view or prompt a reassessment, and you may find your own outlook differs just as widely once you weigh these scenarios against the company’s heavy dependence on ORLADEYO.
Explore 4 other fair value estimates on BioCryst Pharmaceuticals - why the stock might be worth over 8x more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your BioCryst Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free BioCryst Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioCryst Pharmaceuticals' overall financial health at a glance.
Contemplating Other Strategies?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Uncover the next big thing with 18 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com